Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ).
Jenscare Scientific Co., Ltd. has announced the 30-day clinical follow-up results for large annulus patients involved in the TRINITY study, which evaluates the LuX-Valve Plus transcatheter tricuspid valve replacement. The study, presented at New York Valves 2025, enrolled 149 patients globally and demonstrated high device success rates and significant improvements in tricuspid regurgitation grades and cardiac function. These findings underscore the potential of LuX-Valve Plus to enhance treatment outcomes for patients with severe tricuspid regurgitation, marking a significant advancement in the company’s product offerings and strengthening its position in the cardiovascular medical device market.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a joint stock company based in the People’s Republic of China, primarily engaged in the medical device industry. The company focuses on developing innovative solutions for cardiovascular diseases, with a particular emphasis on transcatheter valve replacement technologies.
Average Trading Volume: 560,540
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.89B
For detailed information about 9877 stock, go to TipRanks’ Stock Analysis page.